Okufanele Ukwazi Ngomkhuhlane We-Hepatitis B

Mayelana ne-Hepatitis B Vaccine nokuthi kungani ungayidinga

I-Hepatitis B iyisifo sofuba esithinta isibindi futhi singaba nemiphumela emibi yokuhluleka kwesibindi, i-cirrhosis (ukuqina kwesibindi) nomdlavuza we-hepatocellular (umdlavuza wesibindi). Igciwane le-hepatitis B lihlasela abantu abangaba yizigidi ezingu-400 emhlabeni jikelele, kubandakanya cishe izigidi ezingu-1.5 e-United States.

Igciwane lisakazwa kusuka komuntu kuya komuntu ngokuxhumana ngqo ngqo negazi negciwane lesandulela ngculaza.

Izindlela ezivame kakhulu zokutheleleka zifaka umama kumntwana, ukusetshenziswa kwezidakamizwa ezingu-IV ngezilingo ezihlanganyelwe, ukulimala kwenaliti, nokulala nomuntu one-hepatitis B.

Imishanguzo ye-Hepatitis B

Indlela engcono kakhulu yokuzivikela e-hepatitis B ukuthola ukugonywa kwe-hepatitis B. Kunemigomo emibili etholakalayo e-United States evikela ukulwa nesifo sofuba B: Recombivax HB no-Engerix-B. Kukhona nemishanguzo yokuhlanganiswa evimbela ama-virus amabili. I-Twinrix, isibonelo, ivikela ukulwa nesifo sofuba nesibindi se-hepatitis A.

Obani Abadinga I-Vaccination B?

Noma ubani ofuna ukuvikelwa nge- hepatitis B kufanele agonywe . Kodwa-ke, abanye abantu banethuba elihle lokuchayeka igciwane ngenxa yokuphila kwabo noma uhlobo lomsebenzi wabo.

Umgomo we-HBV manje useyingxenye yesimiso sokugoma njalo futhi unconyelwe zonke izingane. Ngenkathi izingane zingeke zihlangane negazi elithathelwanayo, izingane ezindala nezintsha zingase zibe khona.

Izingane ezithintekile nge-HBV zingase zibe yinkinga. Ngenxa yalokhu, ukugoma ingane ngokumelene nesifo sofuba B kungahlinzeka ngeminyaka eminyaka yokuvikelwa, kugcine ingane iphephile ekutheleleni kuze kube umuntu omdala.

Ingabe I-Vaccine Ye-Hepatitis B Iphephile?

Yebo. Imishanguzo ye-Hepatitis B ine-side effects, uma ikhona, imithwalo yemiphumela emibi.Imithi yeHepatitis B iyingozi kakhulu futhi ayiqukethe igciwane elibukhoma.

Isikhalazo esivamile kakhulu ubuhlungu obuseduze nendawo yomjovo, okuyinto yokuhweba okuhle ukucabangela izinkinga ezinkulu ezivame ukubhekana nokutheleleka kwe-hepatitis B. Njengoba imishanguzo ye-hepatitis B yamukelwa ngawo-1980, iye yaba nesikhathi esibalulekile sokutadisha nokufakazelwa.

I-Vaccine ye-Hepatitis B isebenza kanjani?

Imishanguzo ye-Hepatitis B isebenza ngokufanisa ukutheleleka emzimbeni wakho ngokuletha iphrotheni ebizwa ngokuthi "HBsAg " noma i-hepatitis B surface antigen. Iprotheyini ikhiqizwa ngokufaka izinto ezibonakalayo ezivela ku-virus ye-hepatitis B futhi "zikhulayo" esitokisini semvubelo. Lokhu kukhiqiza i-HBsAg ehlanzekile engakwazi ukubangela ukutheleleka kwangempela kodwa ingabangela ukuphendula kwamagciwane emzimbeni wakho.

Umphumela wukuthi uma uthola igciwane, amasosha omzimba wakho ayokubona futhi alwe nalo. Kuyoba nempumelelo encane yokuphindaphinda, futhi ukutheleleka kufanele kukhishwe. Ngokwezifundo zokugoma ze-hepatitis B, umuntu ogonywe kufanele abe nesisindo sokuvikela phakathi kuka 90% no-95% iminyaka engu-15 noma ngaphezulu.

I-Vaccine inikezwa kanjani?

Ukugonywa kwe-hepatitis B kudinga ukudubula okungama-3 noma ama-4 ngaphezulu kwezinyanga ezingu-6. Umjovo unikezwa emisipha, ngokuvamile ingalo yabantu abadala noma ithanga lezinsana nezingane.

Kuyini i-HBIG?

Ngezinye izikhathi udokotela angase ancoma i-HBIG, i-hepatitis B immune globulin. I-immune globulin uhlobo lokwelapha okugoma olusebenzisa ama-antibodies esikhundleni sama-virus. Lolu hlobo lwe-immunity lubizwa ngokuthi "ukuzivikela okungapheli," ngoba kuvikela ngaphandle kokuthi umzimba wakho uwenze noma yini. I-HBIG inikeza kuphela ukuvikelwa okwesikhashana futhi isetshenziswa kuphela ezimweni ezikhethekile. Ukuze kuvikeleke kangcono, ukugonywa kwesibindi se-hepatitis B kuyindlela ephumelela kakhulu futhi ephumelelayo. Ukuze uthole olunye ulwazi mayelana ne-immune globulin, funda Yini i-Immune Globulin?

Imithombo:

Amasevisi Okulawula Nokuvimbela Izifo. NgoJuni 23, 2008. I-Hepatitis B.

Pickering, LK (ed), The Red Book: Umbiko weKomidi yezifo ezithathelwanayo , 26 e. I-American Academy of Pediatrics, 2003. 318-336.